News
MRK
114.24
+1.49%
1.68
Tectonic Therapeutics: Currently In A Catalyst Vacuum
Seeking Alpha · 6h ago
Trump Trade: Trump announces expansion of TrumpRx.gov
TipRanks · 9h ago
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
TipRanks · 10h ago
Exelixis announces clinical development collaboration with Merck
TipRanks · 11h ago
Exelixis Enters Clinical Development Collaboration With Merck For Its KEYTRUDA QLEX Injection In Combination With Zanzalintinib In The STELLAR-316 Phase 3 Trial
Benzinga · 11h ago
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Merck & Company (MRK) and Cullinan Management (CGEM)
TipRanks · 11h ago
Zoetis Inc. Stock Rallies 4.7%, Outperforms Peers
Dow Jones · 1d ago
Merck's Sac-TMT meets both endpoints in phase 3 endometrial cancer trial
Seeking Alpha · 1d ago
HHS rescinds vaccine panel charter citing 'administrative error'
Seeking Alpha · 1d ago
Trump to announce ‘dramatic expansion’ of TrumpRx offerings, CNBC says
TipRanks · 1d ago
U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide
Benzinga · 1d ago
Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.
Barchart · 1d ago
Why Pfizer Stock Still Looks Deeply Undervalued In 2026
Seeking Alpha · 1d ago
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda
Barron‘s · 1d ago
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial
TipRanks · 1d ago
Merck Announces Pivotal Phase 3 TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints Of OS And PFS In Certain Patients With Endometrial Cancer
Benzinga · 1d ago
Why Is Regeneron Stock Sinking Monday?
Benzinga · 1d ago
Weekly Report: what happened at MRK last week (0511-0515)?
Weekly Report · 1d ago
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer
Barchart · 1d ago
Regeneron hit with late-stage trial setback for Libtayo combo against Merck’s Keytruda
Seeking Alpha · 3d ago
More
Webull provides a variety of real-time MRK stock news. You can receive the latest news about Merck & Co through multiple platforms. This information may help you make smarter investment decisions.
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.